mardi 7 avril 2020

Onco Actu du 7 avril 2020


5.1 TRAITEMENTS - PRÉ-CLINIQUE



Experimental Drug Prevents Doxorubicin from Harming the Heart [NCI]











Scientists enhance new way to overcome resistance to targeted cancer treatments [Institute of Cancer Research]











Turning colon cancer cells around [University of California, Irvine]











5.12.5 IMMUNOTHÉRAPIES - PHARMA



Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type [Merck]











5.12.5.1 IMMUNOTHÉRAPIES - BIOTECH



Ready to declare a definitive comeback in two months, Immunomedics stops PhIII early, recruits new CEO [EndPoints]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Treating bowel cancer during the covid-19 epidemic [University of Leeds]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



European Commission Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment for ALK+ NSCLC [Takeda]











6.15 LUTTE CONTRE LES CANCERS - COVID-19



COVID-19 claims Cancer Research UK funding cuts, forecasting major shortfall [Fierce Biotech]











Opinion: ‘Today our researchers are helping to beat COVID-19 so that ‘tomorrow’ we can get back to beating cancer’ [Cancer Research UK]











Protecting Medical Staff to Ensure Cancer Patients Can Safely Receive Care During the Pandemic [ESMO]











Life 'hanging by a thread' for Italian cancer patients in coronavirus crisis [The Guardian]










Cancer Research UK to cut funding for research by £44m [The Guardian]